Seegene Launches Allplex™ MDRO Assay to Combat Antimicrobial Resistance in Europe

Seegene Introduces Allplex™ MDRO Assay

Overview

On June 1, 2026, Seegene Inc., a prominent player in the field of molecular diagnostics, announced the launch of its innovative Allplex™ MDRO Assay in Europe, marking a significant step in the fight against antimicrobial resistance (AMR). This launch is in alignment with the new EU In-vitro Diagnostic Regulation (IVDR), which aims to ensure the accuracy and safety of diagnostic products in the medical field.

Significance of the Allplex™ MDRO Assay

The Allplex™ MDRO Assay is specifically engineered to reveal the presence of multi-drug-resistant organisms (MDROs) and associated resistance genes in a single test. This groundbreaking technology allows for rapid detection of these harmful pathogens in hospital settings, addressing the rising threat of healthcare-associated infections (HAIs).

With AMR on the rise globally, public health authorities, including the CDC, have underscored the need for enhanced infection control and surveillance measures. The Allplex™ MDRO Assay is poised to meet this demand by facilitating faster first-line PCR screening prior to obtaining results from traditional culture-based methods. This proactive approach allows healthcare providers to implement timely infection prevention measures, vital in safeguarding patient health.

Technology and Efficiency

What sets the Allplex™ MDRO Assay apart is its multiplex PCR technology, which allows for simultaneous detection of multiple pathogens in a single test. Not only does this enhance diagnostic accuracy, but it also provides quantitative information that supports clinical decision-making. The assay's design enables laboratories to process tests efficiently, potentially delivering same-day results depending on the workflow.

Expansion of Seegene's AMR Testing Portfolio

Seegene's new assay complements its existing Allplex™ Entero-DR Assay, creating a combined diagnostic approach that addresses both antimicrobial-resistant intestinal bacteria and high-risk MDRO targets. This holistic methodology strengthens efforts to control infections caused by these resistant organisms while expanding Seegene's overall AMR testing capabilities.

Daniel Shin, Seegene's Executive Vice President and Chief Global Sales and Marketing Officer, stated, "This launch represents more than just a product introduction; it signifies our commitment to expanding our diagnostic portfolio to enhance infection control in hospitals. We aim to develop further diagnostic solutions that can be effectively utilized in clinical practice."

Future Directions

Looking ahead, Seegene plans to broaden its capabilities in diagnosing AMR infections further and adapt to the growing demand for improved infection surveillance and control measures. The company is also in the process of developing an Allplex™ MRSA Assay, targeting Methicillin-resistant Staphylococcus aureus (MRSA), with an anticipated launch in the following year. This initiative reflects Seegene's dedication to creating comprehensive solutions that respond to the evolving challenges presented by infectious diseases.

Conclusion

Seegene's introduction of the Allplex™ MDRO Assay marks a pivotal advancement in the realm of molecular diagnostics, particularly amidst the escalating global concerns surrounding antimicrobial resistance. The ability to quickly diagnose and manage infections caused by MDROs is crucial in today's healthcare landscape, and Seegene is at the forefront of this vital effort.